BioNTech's BNT141 Vaccine Candidate Faces FDA Clinical Hold

TL;DR

FDA puts clinical hold on BioNTech's BNT141 cancer vaccine, halting US trials.

AI Summary

On March 4, 2025, BioNTech SE was informed by the U.S. Food and Drug Administration (FDA) that it has placed a clinical hold on BioNTech's investigational new drug (IND) application for its novel mRNA-based vaccine candidate, BNT141, for the treatment of certain solid tumors. This hold prevents BioNTech from initiating clinical trials with BNT141 in the United States.

Why It Matters

The FDA's clinical hold on BNT141 means BioNTech cannot proceed with U.S. trials for this cancer vaccine, potentially delaying its development and market entry.

Risk Assessment

Risk Level: medium — A clinical hold by the FDA can significantly delay or halt the development of a drug candidate, impacting future revenue streams and investor confidence.

Key Players & Entities

• BioNTech SE (company) — Registrant and subject of the filing
• U.S. Food and Drug Administration (FDA) (company) — Regulatory body that placed the clinical hold
• BNT141 (drug_candidate) — Investigational new drug candidate for cancer treatment
• March 4, 2025 (date) — Date BioNTech was informed of the clinical hold

FAQ

From the Filing

0001776985-25-000006.txt : 20250304 0001776985-25-000006.hdr.sgml : 20250304 20250304160549 ACCESSION NUMBER: 0001776985-25-000006 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250304 FILED AS OF DATE: 20250304 DATE AS OF CHANGE: 20250304 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BioNTech SE CENTRAL INDEX KEY: 0001776985 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: 2M FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39081 FILM NUMBER: 25704250 BUSINESS ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 BUSINESS PHONE: 0049613190840 MAIL ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 6-K 1 form6-kbnt165e4mar2025.htm 6-K Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MARCH 2025 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20‑F or Form 40‑F: Form 20‑F ☒ Form 40‑F ☐ Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(1): ☐ Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(7): ☐ INFORMATION INCLUDED AS PART OF THIS FORM 6-K The U.S. Food and Drug Administration (“FDA”) has informed BioNTech SE (“BioNTech”) that it has placed a clinical hold on BioNTech’s Investigational New Drug application (“IND”) and the related Phase I/IIa clinical trial (NCT06069544) evaluating the safety, tolerability, immunogenicity and efficacy of an investigational RNA-based vaccine (BNT165e) for prevention of P. falciparum malaria in healthy malaria-naive adults. BioNTech has complied with the hold by the FDA and, in accordance with the clinical trial protocol, had proactively paused the study. BioNTech is taking actions to address the FDA’s requests and will work with the FDA to assess next steps. SIGNATURE Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioNTech SE By: /s/ Jens Holstein By: /s/ Dr. Sierk Poetting Name: Jens Holstein Name: Dr. Sierk Poetting Title: Chief Financial Officer Title: Chief Operating Officer Date: March 4, 2025